$111.03 Million in Sales Expected for Genomic Health, Inc. (GHDX) This Quarter

Equities analysts predict that Genomic Health, Inc. (NASDAQ:GHDX) will announce sales of $111.03 million for the current quarter, Zacks Investment Research reports. Seven analysts have provided estimates for Genomic Health’s earnings, with estimates ranging from $110.00 million to $112.52 million. Genomic Health posted sales of $95.62 million in the same quarter last year, which would indicate a positive year over year growth rate of 16.1%. The company is expected to issue its next earnings report on Thursday, August 1st.

On average, analysts expect that Genomic Health will report full-year sales of $445.67 million for the current financial year, with estimates ranging from $442.00 million to $448.00 million. For the next financial year, analysts expect that the business will report sales of $489.33 million, with estimates ranging from $471.81 million to $504.33 million. Zacks Investment Research’s sales calculations are a mean average based on a survey of analysts that that provide coverage for Genomic Health.

Genomic Health (NASDAQ:GHDX) last issued its earnings results on Tuesday, May 7th. The medical research company reported $0.34 EPS for the quarter, topping the consensus estimate of $0.29 by $0.05. The company had revenue of $108.80 million for the quarter, compared to the consensus estimate of $106.75 million. Genomic Health had a net margin of 10.35% and a return on equity of 18.70%. The firm’s revenue for the quarter was up 17.5% on a year-over-year basis. During the same period in the previous year, the firm earned ($0.11) earnings per share.

Several research firms have issued reports on GHDX. Deutsche Bank lowered their target price on shares of Genomic Health from $80.00 to $55.00 and set a “hold” rating on the stock in a research note on Thursday, May 30th. Needham & Company LLC restated a “strong-buy” rating and set a $69.00 target price (down previously from $97.00) on shares of Genomic Health in a research note on Thursday, May 9th. ValuEngine cut shares of Genomic Health from a “buy” rating to a “hold” rating in a research note on Wednesday, May 8th. Canaccord Genuity reaffirmed a “buy” rating and set a $85.00 price target (down previously from $95.00) on shares of Genomic Health in a research report on Wednesday, May 8th. Finally, Zacks Investment Research lowered shares of Genomic Health from a “buy” rating to a “hold” rating in a research report on Tuesday, April 23rd. Eleven research analysts have rated the stock with a hold rating, one has given a buy rating and one has assigned a strong buy rating to the stock. The stock has an average rating of “Hold” and an average target price of $62.63.

GHDX opened at $53.13 on Friday. The company has a current ratio of 5.67, a quick ratio of 5.67 and a debt-to-equity ratio of 0.19. The stock has a market cap of $1.93 billion, a price-to-earnings ratio of 50.60 and a beta of 1.05. Genomic Health has a 52-week low of $48.00 and a 52-week high of $92.18.

In related news, CFO G Bradley Cole sold 11,424 shares of the stock in a transaction that occurred on Tuesday, May 14th. The shares were sold at an average price of $57.17, for a total value of $653,110.08. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Also, Director Bros. Advisors Lp Baker sold 73,735 shares of the stock in a transaction that occurred on Monday, March 11th. The stock was sold at an average price of $74.52, for a total transaction of $5,494,732.20. The disclosure for this sale can be found here. Insiders sold a total of 1,202,954 shares of company stock valued at $84,930,727 over the last three months. 31.30% of the stock is currently owned by insiders.

A number of institutional investors have recently added to or reduced their stakes in the stock. Northwestern Mutual Wealth Management Co. increased its position in shares of Genomic Health by 166.0% in the first quarter. Northwestern Mutual Wealth Management Co. now owns 790 shares of the medical research company’s stock valued at $55,000 after buying an additional 493 shares in the last quarter. Manchester Capital Management LLC acquired a new position in shares of Genomic Health during the first quarter worth about $56,000. Pearl River Capital LLC acquired a new position in shares of Genomic Health during the first quarter worth about $70,000. C M Bidwell & Associates Ltd. acquired a new position in shares of Genomic Health during the first quarter worth about $83,000. Finally, Royce & Associates LP lifted its stake in shares of Genomic Health by 22.8% during the fourth quarter. Royce & Associates LP now owns 1,473 shares of the medical research company’s stock worth $95,000 after purchasing an additional 273 shares in the last quarter. 95.75% of the stock is owned by institutional investors.

Genomic Health Company Profile

Genomic Health, Inc, a healthcare company, provides clinically actionable genomic information to personalize cancer treatment decisions in the United States and internationally. The company develops and commercializes genomic-based clinical laboratory services that analyze the underlying biology of cancer, which allows physicians and patients to make individualized treatment decisions.

Featured Article: What is insider trading?

Get a free copy of the Zacks research report on Genomic Health (GHDX)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Genomic Health (NASDAQ:GHDX)

Receive News & Ratings for Genomic Health Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Genomic Health and related companies with MarketBeat.com's FREE daily email newsletter.